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Maras ¸p o w d e r( M P ) ,ad i ﬀerent type of smokeless tobacco (ST) and prepared from a tobacco of species Nicotiana rustica Linn,
is widely used in Turkey. We aimed to investigate the eﬀects of MP on salivary total sialic acid (TSA) and malondialdehyde
(MDA) levels and to compare these parameters in smokers and MP users (MPUs). The salivary TSA and MDA concentrations
were signiﬁcantly higher in the smokers and MPU than those of control subjects and also in MPU than that of smokers. We have
also observed that as the number of cigarettes consumed and MP amount increases, TSA and MDA levels increase too. In smokers,
MDA values were signiﬁcantly correlated with the number of cigarettes smoked and the duration of smoking. In MPU, both
MDA and TSA levels were signiﬁcantly correlated with the duration of MP use and the amount of daily consumed MP. We have
concluded increased salivary TSA and MDA levels associated in MPU and smokers. Results can help to evaluate harmful eﬀects
of these habits. It is important to point out that bigger change in the measured parameters has been observed for MP use. This
observation may be an important indication of harmful eﬀects of ST use as MP.
1.Introduction
Cigarette smoking is a serious public health hazard. Smoke-
less tobacco (ST) is widely used as chewing tobacco and as
oral snuﬀ in the United States, Western Europe, southern
parts of the Kingdom of Saudi Arabia, southern African
countries, and the Sudan in northeast Africa [1–4]. Also,
in Kahramanmaras ¸, a city located in southern Turkey, ST is
widelyconsumedinsteadofcigarettesmoking, andthis habit
hasbecomeincreasinglypopularamongthemales,especially
among children and male adolescents.
Snuﬀisatermusedtodescribeawidevarietyofproducts
containing ﬁnely ground tobacco as a principal constituent
and other additives. Snuﬀ is either inhaled to the nasal cavity
or dipped in the oral cavity [1]. According to preparation
methods snuﬀ is called diﬀerentially in various regions of
the world. In Kahramanmaras ¸ ,ad i ﬀerent type of ST, locally
called as “Maras ¸ powder (MP)” or “oral powder,” and also
“powder,” has been used for a long time. This powder is
mostly preferred while trying to quit smoking or lessen
it. Tobacco used for manufacture of MP is of the species
Nicotiana rustica Linn (NRL). The leaves of a plant known
as “crazy tobacco” locally are powdered, and this powder
is mixed with the ash of wood especially oak, walnut, or
grapevine. First of all, sun-dried leaves of this plant are
powdered and mixed with the ash in approximately 1:2
or 1:3 proportions (tobacco and oak, resp.). Then, water
is sprinkled onto this mixture for humidiﬁcation. A small
amount of this mixture, sometimes as portion-bag-packed,
(approximately1gaquid)isappliedbetweenthelowerlabial
mucosa and gingival for 4-5 minutes and even as long as
1-2h. This region of the mouth has many capillary vessels;
therefore, nicotine is quickly absorbed into circulation. This
procedure is repeated many times during the day [2, 3].
Snuﬀcontainsanumberofcarcinogens[1].Thetobacco-
speciﬁc nitrosamines (TSNAs) are metabolites of nicotine
and are major carcinogens in tobacco products [1, 4].
Chronic inﬂammation may promote the carcinogenic eﬀect
of these nitrosamines through the generation of reactive
oxygen species (ROS) [4]. On the other hand, ROS and
lipid peroxides have been implicated in the pathogenesis
of a large number of pathological states such as diabetes2 Mediators of Inﬂammation
mellitus, atherosclerosis, heart disease, inﬂammation, and
cancer [5, 6]. Also, inﬂammation is responsible for tissue
injury in pathological conditions ranging from myocardial
infarction to rheumatoid arthritis [7]. It has been suggested
that saliva content changes rapidly in response to systemic
inﬂammation[8,9].Malondialdehyde(MDA)isanindicator
of lipid peroxidation (LPO), and serum and salivary MDA
levels have been reported to correlate in several diseases
and pathology including inﬂammatory conditions [10]. In
addition, according to some reports, total sialic acid level
(TSA) in saliva is increased with oxidative stress (OS) due
to systemic or local eﬀects [11].
On the other hand, TSA has been used as useful
marker for human cancer [12–16]. Elevated concentrations
of serum TSA were suggested as a potent cardiovascular
risk factor in the general population [17, 18]. Also, TSA
is a marker of inﬂammation [19]. These and other several
reports indicate that there is increasing interest to sialic acid
(SA) measurement in a number of branches of medicine to
diagnosing, monitoring systemic health and disease states
[12–14].
SA is the common name for compounds of N-acetylated
derivates of neuraminic acid, which mainly occurs as
nonreducing terminal residues of carbohydrate chains of
glycoproteins (GPs) or glycolipids (GLs) in biological ﬂuids
and cell membranes. SAs have a central role for the function
of biological systems: stabilizing the conformation of GPs
andcellularmembranes,assisting in cell-cellrecognition and
interaction and serving as chemical messengers in tissue and
body ﬂuids, aﬀecting the function of membrane receptor
molecules by developing binding sites for ligands, enzymes,
and so forth, or by blocking such; aﬀecting the functioning,
stability, and survival of GPs in blood circulation. SA is also
an important component of salivary GPs including IgA and
other immunological and acute phase proteins [13, 19, 20].
Saliva is a complex biological ﬂuid composed of a wide
variety of organic and inorganic constituents. Interest in
saliva as a diagnostic ﬂuid has grown exponentially in recent
years.Thishasinpartbeendrivenbytheeasyandsafetywith
which saliva can be collected as compared to blood. Salivary
levelsofvariousbiochemicalparametershavebeenmeasured
in several diseases such as infectious diseases, autoimmune
diseases, cancers, and psychiatric disorders [21, 22]. Thus, it
may be useful to evaluate salivary TSA and MDA levels in
tobacco users.
Although,thereareseveralreportsonbloodLPO[23,24]
and TSA in smokers [3, 17, 25], few studies have been
performed in ST users (STU) [3]. Also, there is no report
available on salivary TSA or MDA in MP users (MPU). In
addition, no previous study was encountered on salivary
MDA and TSA together in smokers. Therefore, the present
study has been undertaken to investigate the eﬀect of ST use
asMPonbothTSAandMDAlevelsinsaliva.Wealsowanted
to compare these parameters between the smokers and STU.
2.MaterialsandMethods
2.1. Subjects. The study was performed at the Department
of Chemistry-Biochemistry, University of Kahramanmaras ¸
S¨ utc ¸¨ u ˙ Imam, Turkey. Saliva samples obtained from smokers
(Group II), MPU (Group III), and healthy control subjects
(Group I), with the latter having never smoked and being
not exposed to any passive smoking in their environment
and also nonusers of MP or ST any form. Also, in Group
II and Group III, there were no subjects who were both
smokers and MPU. The control subjects were selected from
healthy subjects, and their clinical blood proﬁles were within
the normal range, and the general health status was normal.
IndividualswhoaresmokersandSTuserswereclassiﬁedinto
subgroups with respect to the amount of consumed cigarette
or oral powder as follows:
(i) Group II: smokers;
(ii) Group II-A: 1–10cigarettes/day, Group II-B: 11–20
cig-arettes/day, Group II-C: >20 cigarettes/day;
(iii) Group III: MPU;
(iv) Group III-A: 1–10gMP/day, Group III-B: 11–20g
MP/day; Group III-C: >20gMP/day.
Their demographic data is presented in Table 1. All the
subjects in this study were healthy men volunteers recruited
from environment and university students or their friends
and acquaintances. Informed consent was obtained from all
subjects, who were not suﬀering from any disease and were
not on any medications.
2.2. Samples. Unstimulated saliva samples were collected
from each subjects after overnight, before breakfast, and
after the mouth had been rinsed with distilled water.
The collection was carried out at the same time of day
(between 08:00 a.m. and 10:00 a.m.), and in restful and quiet
circumstances. The samples were taken either later the same
day or, with few exceptions, in the next few days (range 0–21
days). Saliva samples were stored at −20◦C until analysis.
2.3. Biochemical Analyses. Saliva TSA was measured with the
Denny’s colorimetric method [26]. In brief, saliva samples
were ﬁrst hydrolyzed in H2SO4 to release SA. The periodate
solution was added and incubated. The excess periodate was
reduced by adding the sodium thiosulfate solution directly
into the sample solution and mixing without delay. The
reaction was completed by the addition of TBA solution
and heating at 100◦C to achieve optimum color production.
The samples were cooled to room temperature in tap water.
Following the addition of acidic butanol, the tubes were
capped and vigorously shaken. Complete phase separation
was achieved by centrifugation at 400×g for 5min. The
butanol phase was carefully removed and assayed colorimet-
rically at 549nm.
LPO was assayed by measurement of MDA, an end
product of fatty acid peroxidation, and reacts with thio-
barbituric acid (TBA) to form a colored complex that has
maximum absorbance at 532nm. In the TBA test reaction,
MDA or MDA-like substances and TBA react together
for production of a pink pigment having an absorption
maximum at 532nm. The reaction was performed at pH
2-3 at 90◦C for 15min. The sample was mixed coldMediators of Inﬂammation 3
Table 1: Demographic variables for the subjects and the salivary TSA and MDA levels∗.
Groups N Age (years)
Duration of
smoking or MP
Use (years)
Consumption of
cigarette
(cigarettes/day) or
MP (g/day)
TSA (µg/mL) MDA
(nmol/mL)
Group I 30 22.23 ±2.45 — — 51.60 ±3.51 0.69 ±0.15
Group II 33 23.80 ±3.43 6.03 ±2.98 16.86 ±6.78 62.60 ± 3.91a 1.59 ±0.28a
Group II-A 10 23.60 ±2.63 4.60 ±2.41 9.20 ±1.87 61.29 ± 4.32a 1.34 ±0.22a
Group II-B 13 23.00 ±3.53 5.85 ±2.76 17.84 ±2.19 62.87 ± 3.28a 1.65 ±0.18a,d
Group II-C 10 25.57 ±4.07 8.43 ±2.99 26.00 ±3.16 64.25 ± 4.33a 1.86 ±0.25a,c
Group III 37 29.03 ±6.46 6.03 ±2.89 19.04 ±7.95 75.52 ±6.86a,b 2.12 ±0.32a,b
Group III-A 10 29.50 ±5.64 4.67 ±0.81 7.50 ±0.94 70.28 ±2.63a,d 1.67 ±0.10a,e
Group III-B 12 29.25 ±7.03 4.50 ±2.15 15.62 ±1.49 73.04 ±5.31a,c,f,g 2.02 ±0.15a,c,f,i
Group III-C 15 28.67 ±6.48 7.80 ±3.02 26.40 ±4.19 79.60 ±6.93a,c,f,g,i,k 2.37±0.21a,c,f,g,h,j
∗Mean values ± standard deviation; X ± SD; TSA: total sialic acid; MDA: malondialdehyde; MP: Maras ¸p o w d e r .
aP < 0.001 versus controls; bP < 0.001 versus Group II; cP < 0.001 versus Group II-AL; dP < 0.01 versus Group II-A; eP < 0.05 versus Group II-A, fP <
0.001 versus Group II-B; gP < 0.001 versus Group II-C; hP < 0.001 versus Group III-A; iP < 0.01 versus Group III-A; jP < 0.001 versus Group III-B; kP <
0.01 versus Group III-B.
Group I: Controls.
Group II: Smokers.
Group II-A: 1–10cigarettes/day; Group II-B: 11–20 cigarettes/day; Group II-C: >20 cigarettes/day.
Group III: MPU.
Group III-A: 1–10gMP/day; Group III-B: 11–20gMP/day; Group III-C: >20gMP/day.
10% (w/v) trichloroacetic acid to precipitate protein. The
precipitate was pelleted by centrifugation and an aliquot of
the supernatant was reacted with an equal volume of 0.67%
(w/v) TBA in a boiling water bath for 10min. After cooling,
the absorbance was read at 532nm [27]. The concentration
of MDA was calculated by the absorbance coeﬃcient of
MDA-TBA complex 1.56 × 105cm−1M−1 a n de x p r e s s e da s
nmoles of MDA per mililiter saliva.
All chemicals in this study were of analytical grade and
purchased from Sigma (Stockholm) or Merck Chemicals Co.
(Germany). All solutions were prepared in deionized water.
2.4. Statistical Analyses. Statistical analyses were performed
with the SPSS 10.0 pocket programme for Windows (SPSS
Inc., Chicago, IL, USA). The data were expressed as mean
values ± standard deviation (X ± SD). The mean values
in the groups were compared with ANOVA and Tukey’s
HSD tests. For correlation analysis, the Pearson correlation
coeﬃcient (r) was used. The level of statistical signiﬁcance
was deﬁned as P < 0.05.
3. Results
In this study, salivary TSA and MDA were measured in ST
users as MP and in smokers and compared with healthy
controls who were nonsmokers and nonusers of ST. The
results are given in Tables 1 and 2. The salivary TSA and
MDAconcentrationsweresigniﬁcantlyhigherinthesmokers
(P < 0.001) and MPU (P < 0.001) than those of control
subjects. Also, salivary TSA and MDA levels in MPU group
were higher than those in smokers (P < 0.001).
The mean salivary TSA and MDA levels were found to
be lowest in the control group and highest in the MPU.
The TSA and MDA levels increased with the number of
cigarettes consumed and also the amount of MP used.
There were no statistically signiﬁcant diﬀerences in TSA
levels between subgroups in smokers (P > 0.05) whereas
signiﬁcant diﬀerences were found in all subgroups of MPU
(P < 0.05), except for the diﬀerence between Group III-A (1–
10g MP/day) and Group III-B (1–20gMP/day) (P > 0.05).
There were statistically signiﬁcant diﬀerences in the MDA
levels of all subgroups in MPU and also in smokers except
for the diﬀerence between Group II-B (11–20 cigarettes/day)
a n dG r o u pI I - C( >20 cigarettes/day).
When compared the salivary TSA and MDA levels
between subgroups of smokers and MPU, statistically signif-
icant diﬀerences were found in all groups (P < 0.05) except
for the diﬀerences between Group III-A and Group II-B,
a n da l s oG r o u pI I - C( P > 0.05). There was no statistically
signiﬁcant diﬀerence in the MDA levels between Group II-C
and Group III-B (P > 0.05).
Incorrelationanalysis,therewerepositive andimportant
correlations between the MDA and TSA levels of all three
groups. We have also observed that as the number of
cigarettes consumed and MP amount increased, the salivary
TSA and MDA levels also increased. In Group II, signiﬁcant
correlations were observed between MDA levels and number
of cigarettes smoked and duration of smoking. In Group III,
both MDA and TSA levels were signiﬁcantly correlated with4 Mediators of Inﬂammation
the duration of MP use, and also correlated with the amount
of daily consumed MP.
4. Discussion
Our study shows that salivary TSA and MDA levels were
signiﬁcantly increased in smokers and MPU. This is the ﬁrst
study speciﬁcally meant to evaluate the salivary TSA and
M D Al e v e l st o g e t h e ri nb o t hs m o k e r sa n dS T Uo rM P U .
ST is an alternative way of smoking. The public believes
that this smokeless powder taken orally is less harmful than
cigarette smoking. Also, some individuals prefer it to reduce
or quit smoking. Banning smoking in public buildings,
restaurants, conveyances, and many oﬃces and workplaces
also contributed to ST use as an alternative tobacco habit.
Smoking has currently been established to be a car-
diovascular risk factor [28, 29]. On the other hand, raised
serum TSA concentration has been proposed to be a strong
predictor of cardiovascular mortality [17, 18]. Tobacco
smoke contains approximately 4000 constituents. Nicotine
is one of the most pharmacologically active tobacco com-
ponents with a wide range of cardiovascular eﬀects [30].
Some investigators reported that nicotine is one of the
risk factors in the development of atherosclerosis [31].
Therefore, elevated salivary TSA levels might be reﬂective
of cardiovascular disease (CVD) risk in MPU and smokers.
On the other hand, nicotine content of NRL is high. For
example, nicotine content of NRL is about 6–10 fold higher
than Nicotiana tobacum L., which is present in the cigarette
tobacco [32]. In this study, salivary TSA levels in MPU were
higherthanthoseofsmokers.WhenMPisconsideredtohave
a high nicotine content, it is obvious that harmful eﬀects
should be more pronounced. Although the reason for the
association of TSA with CVD is unclear, it can be explained
that a major quantity of TSA in saliva is derived from
the terminal oligosaccharide chain of several of the acute-
phase proteins (such as alpha 1-acid glycoprotein, alpha
1-antitrypsin, alpha 1-antichymotrypsin and ceruloplasmin
which are all sialylated GPs [13, 19, 20]). It has been
suggestedthatelevatedserumTSAmayreﬂectanacutephase
response [13, 19]. An increased concentration of acute phase
reactants is caused by an acute inﬂammatory disease or by
an injury [13, 18]. Lindberg et al. showed that the positive
correlation between alpha 1-antitrypsin and smoking and
haptoglobin but not orosomucoid [33]. But, we did not
measure the acute phase reactants, in this study. However,
elevated salivary TSA levels might be reﬂected to CVD risk
in smokers and MPU. There have been a lot of studies on
serum TSA in smokers, that, generally, elevated serum TSA
has been reported [3, 17, 25, 33]. However, previous reports
concerning serum TSA levels in smokers are somewhat
controversial. Patel et al. reported that TSA levels were not
aﬀected by smoking habit [34]. On the other hand, limited
studies have been performed on serum TSA in STU and
salivary TSA in smokers. Recently, we have reported that
TSA levels are elevated in serum of STU as MP [3]a n d
of smokers [25] compared to controls. Also, it has been
observed that salivary TSA levels are elevated of smokers, but
not signiﬁcant. In addition, we have found that serum and
salivary TSA levels parallel one another in alcoholics [25]. To
our knowledge, there is no report available on salivary TSA
in STU, so this is the ﬁrst study which evaluates the salivary
TSA levels in STU or MPU.
Tobacco use has been estimated to account for 30% of
the worldwide cancer burden [35]. Snuﬀ contains a number
of carcinogens, principally the most abundant ones, the
TSNAs, which have been shown to be potent carcinogens
in experimental animals. In addition, snuﬀ contains other
carcinogens including aliphatic and aromatic hydrocarbons,
formaldehyde, ketones, alcohols, phenols, amines, amides,
metals, radioelements (e.g., polonium-210, uranium-235
and 238) and polyaromatic hydrocarbons [1, 36, 37]. Several
epidemiological and laboratory studies have documented
that use of snuﬀ is associated with an increased risk for
cancers of the oral cavity, larynx, and pharynx [1, 36].
There are also indications for an increased risk of cancer
of esophagus, pancreas, renal pelvis, and urinary bladder
among snuﬀ users [38]. In addition, smoking was reported
to be a risk factor for oral cavity and esophageal cancers and
liver cirrhosis as well as lung cancer [39]. The evidence so
far accumulated demonstrates that tobacco habits increase
endogenous N-nitroso compounds formation, thus adding
to the burden of exposure by preformed carcinogenic these
in tobacco products [40].
On the other hand, serum TSA has also been used
as a tumor marker for a number of diﬀerent cancers
including colorectal, prostate, and breast cancers [14, 15].
Cell surfaces and membrane components play a promi-
nent role in neoplastic behavior. Neoplasms often have an
increased concentration of TSA on the tumor cell surface,
and sialoglycoproteins are shed or secreted by some of these
cells, which increases the concentration in blood or saliva
[14]. Moreover, cancer cells have been associated with an
increased activity of sialytransferase, leading to an increased
amountofTSAonthecellsurface,thusincreasingtheplasma
or salivary concentration [19, 41]. TSA concentrations have
been reported to be related not only to diagnosis, but also
to staging, prognosis, and detection of early recurrence
[14]. It has been suggested that evaluations of the serum
glycoconjugate levels may be useful in early detection and
staging of oral precancerous conditions and oral cancer [16]
which are often associated with ST use or smoking.
Recently, Latha et al. showed that prolonged exposure
of rats to cigarette smoke resulted in signiﬁcant alteration
in the metabolism of GPs and glycosaminoglycans (GAGs)
in diﬀerent tissue [39]. SA is an important component of
salivary GPs which play an important role in the properties
and functions of saliva [21]. Some of these GPs are known to
act as scavenger molecules [42, 43], and sialoglycoconjugates
which are synthesized in salivary glands may play a role in
•OH scavenging [43, 44]. Morever, it was clearly shown that
the SA in the GPs is an essential moiety to scavenge •OH
[43].
In this study, our results show that cigarette smoke or
MP use caused an increase in the salivary LPO. We found
that salivary MDA levels were signiﬁcantly higher in tobaccoMediators of Inﬂammation 5
Table 2: Correlation coeﬃcients.
Compared Parameters Group I (controls) Group II (smokers) Group III (MPU)
Age versus TSA 0.127 −0.134 −0.022
Age versus MDA 0.124 0.205 −0.066
TSA versus MDA 0.722∗∗∗ 0.517∗∗ 0.756∗∗∗
TSA versus consumed daily cigarette or MP 0.279 0.586∗∗∗
MDA versus consumed daily cigarette or MP 0.702∗∗∗ 0.872∗∗∗
TSA versus duration of smoking or MP use 0.268 0.564∗∗∗
MDA versus Duration of Smoking or MP use 0.454∗ 0.474∗∗
consumed daily cigarette or MP versus duration of smoking or MP use 0.434∗ 0.537∗∗∗
Age versus consumed daily cigarette or MP 0.198 0.062
Age versus duration of Smoking or MP Use 0.477∗∗ 0.480∗∗
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
groups than healthy controls, and also signiﬁcantly higher in
MPU than smokers. Guentsch et al. reported that smoking
enhanced LPO in the saliva [45]. Also, LPO products and
tobacco-derived carcinogens have been found in the saliva of
tobacco chewers (35). On the other hand, saliva is reported
to be suitable to detect the body’s OS level [46].
Nicotine and other compounds in the tobacco that
induce intracellular OS recognized as the important agents
involved in the damage of biological molecules. These
compounds are inducing many cellular processes mediated
through ROS [47–49]. Some studies shown that nicotine
increases ROS in a time and concentration-dependent man-
ner. Barr and co workers have reported that as low as 0.1µM
concentration of nicotine induces ROS by approximately
35%; however, signiﬁcant amount of increase in ROS is
observed at 1 and 10µM with 54% and 80% respectively
[47].Bagchietal.reportedthatSTextractproducesoxidative
tissue damage [48]. Yildiz et al. demonstrated that nicotine
and ST extract increased MDA generation [49]. They have
assessed the generation of ROS, following treatment with
4, 0.8, and 0.08mg of nicotine and ST extract containing
the same amounts of nicotine. They have shown that all
preparations of ST extract signiﬁcantly increased MDA
generation while only 4mg of nicotine were suﬃcient to
increase MDA generation. Finally, they have reported that
nicotine is less toxic than ST extract that contained the same
amountofnicotine.Inanotherstudy,increasedplasmaMDA
levels were reported in MPU compared with the controls
[50]. Our observations conﬁrm the results of these studies
which suggest that nicotine and other components of ST
increase the LPO. In our study, MDA levels were signiﬁcantly
correlated with the duration of MP use and the amount of
daily consumed MP. At the same time, we have observed
signiﬁcant correlations between MDA levels and number
of cigarette smoked and duration of smoking. However,
Nielsen et al. found that there was signiﬁcant correlation
between plasma MDA and the number of hours of exposure
to cigarette smoke, but no correlation between plasma MDA
and the number of cigarette smoked [51].
In this study, salivary TSA levels paralleled with MDA
levels. In MPU, both MDA and TSA levels were signiﬁcantly
correlated with the duration of MP use and the amount
of daily consumed MP. But, in smokers, only MDA values
were signiﬁcantly correlated with the number of cigarettes
smoked and the duration of smoking. In addition, we found
a signiﬁcant correlation between TSA and MDA of all three
groups. On the other hand, salivary TSA level has been
reported to increase with OS due to systemic or local eﬀects
[11] and plasma TSA to positively correlate with LPO [52].
ROS and other reactive species are important coordinators
of the inﬂammatory response [5]. Cigarette smoke increases
production of oxygen-free radicals by polymorphonuclear
leukocytes [51]. In the literature, leukocyte counts were
reported to be signiﬁcantly higher in the smokers [53, 54].
Also, it has been suggested that the increased leukocyte
counts, found in MPU, may be an indicator of inﬂammatory
events in various tissues [50]. On the other hand, it has
been reported that salivary MDA levels reﬂect circulating
MDA levels well in systemic inﬂammatory diseases [10].
One of the possible reasons in the increase of salivary MDA
may be a result of oxidative damage of the salivary glands.
Possibly, continuous local irritation by tobacco can lead to
injury-related chronic inﬂammation and OS. Morever, tissue
injury can itself cause more oxidant generation which may
contribute to a worsening of the injury [6]. In addition, an
increase in salivary OS may be related to the alteration of
salivarysecretionandqualitativechangesinsalivaryproteins.
However, we did not measure these parameters, in this study.
Saliva is not only the ﬁrst biological ﬂuid to encounter
inhaled cigarette smoke or dipped MP, but also an impor-
tant organism ﬂuid which has closer interaction with the
gastrointestinal tract. Therefore, MP has hazardous eﬀects
on the gastrointestinal tract as well as oral mucosa. Also,
salivary ROS, which has been originated in both the used
tobaccoproductsandmucosalinﬂammation,causeoxidative
damage in various cells, organs, systemic circulation, and
all body. Consistent with our opinion, it has been suggested
that MP could have carcinogenic eﬀects on the oral mucosa
and gastrointestinal tract, atherogenic eﬀects on endothelial
cells, and it could cause many other systemic disorders by the
reason of MP increases OS [50].
Taking into consideration that the studies mentioned
above, increased salivary TSA and MDA levels in smokers
and MPU, might be related to various diseases, for example,6 Mediators of Inﬂammation
various cancers and CVD, and both of which are also
often associated with elevated TSA or MDA levels and with
smoking or ST use. Morever, our ﬁndings suggest that there
may be a closer interaction between the inﬂammatory events
and smoking or MP use. It has been reported that the
changes in saliva components were net eﬀects caused by the
cancer, systemic diseases, or medications as well as mucosal
inﬂammations [55], which conﬁrms the our opinion.
5. Conclusions
From the results obtained we can conclude that increased
salivary TSA associated with LPO in MPU and smokers. This
may be an indication that MP use has harmful eﬀects at
least of cigarette smoking. We can say that MP may be more
harmful than smoking because we found that salivary TSA
and MDA levels in MPU group were higher than those in
smokers. In addition to that, the correlations between the
measured parameters were bigger in MPU than those in
smokers.
Besides an inﬂammation marker, TSA may be concluded
as an alternative OS marker in tobacco exposure since the
increase in TSA levels in saliva has been found to be in well
accordance with MDA. Another important point is that the
chronic diseases which are resulted as the harmful eﬀects of
MP usually happen later in life. Therefore, a saliva-based test
could prove very useful for early detecting and monitoring of
health eﬀects of these habits since saliva is a readily available
specimen. Thus, we suggest that salivary TSA and MDA may
be used as useful markers for this purpose. In addition, this
study is important because the ﬁnding draws attention to a
signiﬁcant potential public health hazard. However, we think
the results of the study should be investigated further in
larger samples.
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